Prognostic significance of in situ and plasma levels of transforming growth factor β1, -2 and -3 in cutaneous melanoma

Tang,Ming‑Rui; Wang,Yu‑Xin; Guo,Shu; Han,Si‑Yuan; Li,He‑Huan; Jin,Shi‑Feng

doi:10.3892/mmr.2015.3250

June-2015 Volume 11 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2015 Volume 11 Issue 6

Full Size Image

Article

Prognostic significance of in situ and plasma levels of transforming growth factor β1, -2 and -3 in cutaneous melanoma

Authors:
- Ming‑Rui Tang
- Yu‑Xin Wang
- Shu Guo
- Si‑Yuan Han
- He‑Huan Li
- Shi‑Feng Jin
View Affiliations / Copyright

Affiliations: Department of Plastic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Pages: 4508-4512
|
Published online on: January 26, 2015

https://doi.org/10.3892/mmr.2015.3250
Expand metrics +

Abstract

Melanoma is an aggressive type of cutaneous malignancy. Transforming growth factor (TGF)‑β has been demonstrated to be an important mediator of tumor progression. However, to the best of our knowledge, the systemic roles of plasma TGF‑β and TGF‑β in situ have not been investigated in Han Chinese melanoma patients. The results of the present study demonstrated that the in situ and plasma levels of TGF‑β1, TGF‑β2 and TGF‑β3 protein and messenger RNA were significantly elevated in tumor tissues compared with those of normal tissues. The survival rates of the patients which were triple‑positive (TGF‑β1+, TGF‑β2+ and TGF‑β3+) were found to be markedly decreased compared to those which were single‑ (TGF‑β1+, TGF‑β2+ or TGF‑β3+) or double‑positive (TGF‑β1+, TGF‑β2+; TGF‑β2+, TGF‑β3+; or TGF‑β1+, TGF‑β3+). These results may therefore contribute to the use of TGF‑β as a prognostic biomarker, and to the development of novel therapies for melanoma treatment.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Diffey BL: The future incidence of cutaneous melanoma within the UK. Br J Dermatol. 151:868–872. 2004. View Article : Google Scholar : PubMed/NCBI
3	Sousa JF, Torrieri R, Silva RR, et al: Novel primate specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool. PLoS One. 5:e135102010. View Article : Google Scholar
4	Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 1:169–178. 2000. View Article : Google Scholar
5	Derynck R and Zhang YE: Smad-dependent and Smad independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
6	Wu MY and Hill CS: Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev Cell. 16:329–343. 2009. View Article : Google Scholar : PubMed/NCBI
7	Roberts AB and Wakefeld LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA. 100:8621–8623. 2003. View Article : Google Scholar : PubMed/NCBI
8	Busse A and Keilholz U: Role of TGF-β in melanoma. Curr Pharm Biotechnol. 12:2165–2175. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lasfar A and Cohen-Solal KA: Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis. 31:1710–1717. 2010. View Article : Google Scholar : PubMed/NCBI
10	Malaponte G, Zacchia A, Bevelacqua Y, et al: Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression. Oncol Rep. 24:81–87. 2010. View Article : Google Scholar : PubMed/NCBI
11	Goel MK, Khanna P and Kishore J: Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 1:274–278. 2010. View Article : Google Scholar
12	Massagué J: TGFbeta in Cancer. Cell. 134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
13	Leivonen SK and Kähäri VM: Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer. 121:2119–2124. 2007. View Article : Google Scholar : PubMed/NCBI
14	Albino AP, Davis BM and Nanus DM: Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res. 51:4815–4820. 1991.PubMed/NCBI
15	Bursch W, Oberhammer F and Schulte-Hermann R: Cell death and its protective role in disease. Trends Pharmacol Sci. 13:245–251. 1992. View Article : Google Scholar : PubMed/NCBI
16	Schmid P, Itin P and Rufli T: In situ analysis of transforming growth factor-betas (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis. 16:1499–1503. 1995. View Article : Google Scholar : PubMed/NCBI
17	Van Belle P, Rodeck U, Nuamah I, Halpern AC and Elder DE: Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol. 148:1887–1894. 1996.PubMed/NCBI
18	Rodeck U, Bossler A, Graeven U, et al: Transforming growth factor b production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54:575–581. 1994.PubMed/NCBI
19	Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U and Orfanos CE: Elevated plasma levels of transforming growth factor (TGF)-b1 and TGF-b2 in patients with disseminated malignant melanoma. Br J Cancer. 77:1492–1494. 1998. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Prognostic significance of in situ and plasma levels of transforming growth factor β1, -2 and -3 in cutaneous melanoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles